SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
ChipMOS Technologies reported second quarter 2026 financial results with revenue of NT$7,383.1 million (up 28.7% year-over-year), gross margin expansion to 18.0%, and net earnings of NT$1.28 per share, marking a return to profitability from a loss in Q2 2025.
View raw filing on EDGAR →This is a clear earnings release disclosing quarterly financial results for the three and six months ended June 30, 2026. The press release, attached as Exhibit 99.1, presents net sales of $102.9 million, net income of $1.5 million ($0.07 per share), adjusted EBITDA of $9.8 million, and other key operating metrics. Item 2.02 explicitly states the company "issued a press release announcing its results for the three months and six months ended June 30, 2026," which is the hallmark of an earnings_release disclosure.
View raw filing on EDGAR →This is a clear earnings release disclosing Kardigan's financial results for the fiscal quarter ended June 30, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing second quarter 2026 financial results with detailed operating expenses, net loss ($116.2 million), cash position ($660.7 million), and per-share metrics. The disclosure is material to investors as it provides the company's quarterly financial performance and cash runway guidance through multiple clinical milestones.
View raw filing on EDGAR →Cardinal Infrastructure Group Inc. issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026, including record quarterly revenue of $226.9 million (up 114% year-over-year), adjusted EBITDA of $28.1 million, and updated 2026 full-year guidance to $880–$900 million in revenue.
View raw filing on EDGAR →Upstream Bio disclosed its Q2 2026 financial results and business highlights on August 11, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes quarterly financial statements (balance sheet and statements of operations), operating metrics (R&D and G&A expenses, net loss of $39.7 million), and clinical development updates for its lead program verekitug. This is a standard earnings release for a clinical-stage biotech company, filed under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →Aura Biosciences issued a press release announcing its financial results for Q2 2026 (quarter ended June 30, 2026), disclosing a net loss of $45.6 million, cash position of $323.8 million, R&D expenses of $30.7 million, and G&A expenses of $17.3 million, along with business highlights and operational updates.
View raw filing on EDGAR →This is a clear earnings release disclosing Hemab Therapeutics' financial results for Q2 2026 (quarter ended June 30, 2026), issued on August 11, 2026. The Item 2.02 filing includes a press release (Exhibit 99.1) announcing quarterly financial results including cash position ($457.5M), R&D expenses ($20.3M), G&A expenses ($5.7M), and net loss ($24.2M or $0.80 per share), along with corporate and pipeline updates. This is a standard earnings release disclosure material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →CalciMedica issued a press release on August 11, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, disclosing Q2 2026 cash position ($18.6 million), R&D expenses ($2.1 million), G&A expenses ($1.9 million), and net loss ($7.7 million or $0.45 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →Tango Therapeutics issued a press release on August 11, 2026 disclosing its financial results for the quarter ended June 30, 2026, including consolidated statements of operations and balance sheets. The filing explicitly states this is being disclosed pursuant to Item 2.02 (Results of Operations and Financial Condition), and the press release is furnished as Exhibit 99.1. This is a standard quarterly earnings release for a public company, disclosing net loss of $55.3 million for Q2 2026 and cash position of $1.0 billion, along with clinical pipeline updates and corporate milestones.
View raw filing on EDGAR →This is a straightforward earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure explicitly states that Ambiq "issued a press release to report financial results for its second quarter ended June 30, 2026," with the press release attached as Exhibit 99.1. The exhibit contains detailed financial statements (consolidated balance sheets, statements of operations, cash flows), management commentary, and forward guidance for Q3 2026. The results show material growth (90% YoY net sales increase, gross profit more than doubled) and would affect a reasonable investor's assessment of the company's financial performance and trajectory.
View raw filing on EDGAR →Sagimet disclosed Q2 2026 financial results via press release (Exhibit 99.1), reporting a net loss of $13.953 million for the quarter and $24.6 million for the six-month period, with a cash position of $257.6 million, along with corporate updates on clinical trial progress and equity financing.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (three months ended June 30, 2026) filed under Item 2.02 Results of Operations and Financial Condition. The press release discloses quarterly financial results including revenue of $5.7 million, net loss of $13.9 million ($0.14 per share), R&D and G&A expenses, and cash position of $155.2 million. The filing includes audited financial statements (Statements of Operations and Balance Sheets) as Exhibit 99.1, which is the standard format for earnings releases on Form 8-K.
View raw filing on EDGAR →This is a classic earnings release disclosure under Item 2.02. The company issued a press release on August 11, 2026 disclosing financial results for the quarter ended June 30, 2026, including collaboration revenue, R&D and G&A expenses, net loss of $6.6 million, and cash position of $43.2 million. The filing includes condensed balance sheets, statements of operations, and cash flow statements for the interim period, along with corporate highlights and forward-looking guidance on clinical trial milestones. This is material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →Neuronetics disclosed Q2 2026 financial results via press release, reporting total revenue of $41.6 million (up 9.1% year-over-year), improved gross margin to 51.1%, reduced net loss to $3.4 million from $10.1 million, and achievement of positive adjusted EBITDA of $0.3 million, along with updated full-year 2026 guidance.
View raw filing on EDGAR →This is a clear earnings release disclosing Kalaris Therapeutics' financial results for the quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states the company "issued a press release announcing the Company's financial results for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated statements of operations and balance sheets, along with detailed discussion of R&D expenses ($9.0M), G&A expenses ($3.4M), net loss ($11.5M), and cash position ($93.5M). This is a material disclosure affecting investor assessment of the registrant's financial condition and operational performance.
View raw filing on EDGAR →LB Pharmaceuticals issued a press release on August 11, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed statements of operations and balance sheet data. The disclosure includes quarterly R&D expenses ($44.1M vs. $2.4M prior year), G&A expenses ($9.8M vs. $2.4M), and net loss ($51.6M vs. $4.9M), along with cash position and operational updates. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial condition and burn rate.
View raw filing on EDGAR →This is a standard quarterly earnings release for Q2 2026 (three months ended June 30, 2026) filed on August 11, 2026. The disclosure includes financial results (net loss of $44.1 million, R&D expenses of $35.9 million, G&A expenses of $11.7 million), balance sheet data (cash position of $384.3 million), and condensed consolidated statements of operations. The full press release is attached as Exhibit 99.1, which is the typical format for earnings disclosures under Item 2.02.
View raw filing on EDGAR →Diodes disclosed second quarter 2026 financial results on August 5, 2026, reporting revenue of $445.5 million (up 22% year-over-year), gross profit margin of 33.1%, and GAAP net income of $1.00 per diluted share, along with forward guidance for Q3 2026. The earnings conference call transcript and detailed financial metrics were furnished as Exhibit 99.1.
View raw filing on EDGAR →Immunic reported financial results for Q2 2026 ended June 30, 2026, and provided a corporate update via press release.
View raw filing on EDGAR →The filing's primary disclosure under Item 2.02 is the announcement of second quarter 2026 financial results via press release dated August 11, 2026, with detailed quarterly operating results, portfolio performance metrics, and earnings per share data. While the filing also discusses a pending merger with Chicago Atlantic BDC, Inc. and a recent Koach transaction, the core Item 2.02 disclosure and the press release (Exhibit 99.1) center on quarterly earnings announcement, making this an earnings_release event.
View raw filing on EDGAR →This is a CEO Letter to Shareholders dated August 11, 2026, that discloses complete first-half 2026 financial results including revenues ($0.9M, down 17% YoY), operating expenses (R&D up 29%, S&M up 38%), net loss ($4.4M vs. $3.2M prior year), and cash position ($7.7M). The letter explicitly states "we are providing our complete financial results" and references a prior preliminary revenue update. This constitutes a material earnings disclosure for the six-month interim period ended June 30, 2026.
View raw filing on EDGAR →The filing discloses Protara Therapeutics' financial results for the second quarter ended June 30, 2026, including a net loss of $21.7 million ($0.36 per share), R&D expenses of $17.0 million, G&A expenses of $6.4 million, and cash position of $161.9 million. The press release attached as Exhibit 99.1 is a standard quarterly earnings announcement with financial statements and business updates, filed under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →TransAct Technologies issued a press release on August 11, 2026, announcing preliminary financial results for Q2 2026 (three and six months ended June 30, 2026), disclosing net sales of $13.9 million, FST recurring revenue of $3.4 million (up 13% YoY), operating loss of $(54) thousand, and net loss of $(50) thousand, while reiterating 2026 revenue guidance of $55–$57 million and increasing adjusted EBITDA guidance to $1.5–$2.0 million.
View raw filing on EDGAR →This is a news release dated August 10, 2026, disclosing Silvercorp's financial and operating results for Q1 Fiscal 2027 (three months ended June 30, 2026). The release reports adjusted net income of $53.9 million ($0.24 per share), cash flow from operating activities of $61.7 million, revenue of $138.7 million (70% increase year-over-year), and detailed production metrics across multiple mining operations. This is a classic earnings release announcing quarterly financial results, material to investors assessing the company's financial performance and operational status.
View raw filing on EDGAR →This is a press release announcing EDENOR's financial results for the six-month period ended June 30, 2026, disclosing EBITDA of ARS 313,747 million, net profit of ARS 157,132 million, and key operating metrics. The document explicitly states "the Board of Directors...approved today its financial statements for the six-month period ended June 30, 2026" and presents comparative financial performance against the prior-year period, making this a periodic interim earnings disclosure material to investors.
View raw filing on EDGAR →This is a clear earnings release disclosing unaudited financial results for Q4 and full fiscal year 2026 ended June 30, 2026. The press release (Exhibit 99.1) announces net sales of $11.1 billion in Q4'26 (vs. $5.8 billion in Q4'25), net income of $1,178 million (vs. $195 million in Q4'25), and full-year fiscal 2026 results of $39.1 billion in net sales and $2.2 billion in net income. The filing includes condensed consolidated financial statements and forward-looking guidance for Q1 and full fiscal 2027, which are material to investors assessing the registrant's financial performance and trajectory.
View raw filing on EDGAR →Aquestive Therapeutics reported second quarter 2026 financial results, including total revenues of $13.8 million (up 38% year-over-year), net loss of $22.9 million, and cash position of $98.5 million, along with operational updates on key programs including Anaphylm NDA resubmission and AQST-108 development.
View raw filing on EDGAR →Neurogene issued a press release on August 11, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing Q2 2026 financial results including R&D expenses ($25.5M), G&A expenses ($11.2M), net loss ($34.5M), and cash position ($225.4M). The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial metrics and material clinical trial updates for the company's lead program NGN-401.
View raw filing on EDGAR →Big Sky Industrial issued a press release on August 11, 2026 disclosing financial results for the three and six months ended June 30, 2026, including revenue of $2.1 million, net loss of $2.3 million, and adjusted EBITDA of $(0.9) million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed quarterly financial metrics, production data, and operational highlights.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure announces "financial results for the second quarter of 2026" with the full press release furnished as Exhibit 99.1. The press release reports Q2 2026 revenue of $23.0 million (down from $35.4 million in Q2 2025), a net loss of $9.4 million (versus net income of $3.6 million in Q2 2025), and revised full-year 2026 guidance to $99-103 million from $101-105 million. This is a material event affecting investor assessment of the company's financial performance and outlook.
View raw filing on EDGAR →The 8-K discloses under Item 2.02 the company's financial results for the quarter ended June 30, 2026, with a press release attached as Exhibit 99.1. The filing reports Q2 2026 net loss of $2.8 million ($0.54 per share) and H1 2026 net loss of $7.1 million ($1.38 per share), along with detailed operating expense breakdowns and balance sheet information. This is a standard earnings release disclosure material to investors assessing the registrant's financial condition and operational performance.
View raw filing on EDGAR →The 8-K discloses TON Strategy Company's second quarter 2026 financial results via a press release dated August 11, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The filing reports Q2 2026 revenue of $15.0 million (primarily from Gram staking), gross profit of $14.3 million, and net income from continuing operations before taxes of $83.5 million, along with operational highlights including Gram holdings of 230.5 million units valued at approximately $369.5 million. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance and treasury strategy.
View raw filing on EDGAR →The 8-K discloses quarterly financial results for the three and nine months ended June 28, 2026 via Item 2.02 (Results of Operations and Financial Condition). The press release (Exhibit 99.1) presents Q3 fiscal 2026 revenue of $9.7 million, net income of $1.3 million ($0.18 per diluted share), gross margin of 34.2%, and full-year guidance of $43–$45 million in revenue. This is a standard earnings release disclosure material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →The 8-K discloses Q2 2026 financial results for the quarter ended June 30, 2026, with revenue of $2.1 million (up 103% YoY), gross profit of $1.5 million (up 217% YoY), and improved net loss of $(2.3) million (39% improvement). The earnings release is attached as Exhibit 99.1 and filed under Item 2.02 Results of Operations and Financial Condition, which is the standard Item for earnings releases. The material financial improvements and strategic developments (ATF declassification, WrapShield platform, Frenel investment) make this disclosure material to investors.
View raw filing on EDGAR →IZEA disclosed Q2 2026 financial results via press release on August 11, 2026, showing revenue of $5.8 million (down 36% YoY), a net loss of $0.7 million (versus prior-year net income of $1.2 million), and Adjusted EBITDA of $(0.4) million (versus $1.3 million). The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The results are material to investors as they reflect significant revenue decline and a swing from profitability to loss.
View raw filing on EDGAR →This is a clear earnings release disclosing Intensity Therapeutics' financial results for the three and six months ended June 30, 2026. The filing explicitly states "On August 11, 2026, Intensity Therapeutics, Inc. released its financial results for the three and six months ended June 30, 2026" with a press release attached as Exhibit 99.1. The press release includes quarterly financial data (R&D expenses, G&A expenses, net loss, cash position) and is material to investors assessing the company's financial condition and operational progress.
View raw filing on EDGAR →Aramark issued a press release on August 11, 2026, announcing third quarter fiscal 2026 financial results for the quarter ended July 3, 2026. The disclosure includes revenue ($5.1 billion, +9% YoY), operating income (+18%), adjusted EPS (+29%), and cash flow metrics, along with updated full-year guidance raising organic revenue growth expectations to +9% to +10%. This is a standard quarterly earnings release material to investors' assessment of the company's financial performance and outlook.
View raw filing on EDGAR →GrowGeneration published a press release on August 11, 2026 disclosing second quarter 2026 financial results (net sales of $43.2 million, net loss of $2.0 million, positive Adjusted EBITDA of $0.3 million) and updated full-year 2026 guidance (revenue of $162–$168 million, Adjusted EBITDA of $2–$3 million). The filing is Item 7.01 (Regulation FD Disclosure) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes consolidated balance sheets and statements of operations for the periods ended June 30, 2026.
View raw filing on EDGAR →Lithium Argentina announced Q2 2026 financial results with net income of $1.3 million, operating cash flow of $142 million, and adjusted EBITDA of $110 million for the Cauchari-Olaroz operation, along with production of 9,280 tonnes of lithium carbonate and forward-looking guidance.
View raw filing on EDGAR →Keenova Therapeutics plc disclosed its financial results for the second quarter ended June 30, 2026, under Item 2.02, reporting net sales of $517 million from continuing operations, Acthar Gel net sales of $205 million (17% growth), XIAFLEX net sales of $150 million, and a loss from continuing operations of $221 million. The filing includes revised full-year 2026 guidance raising Acthar Gel growth to 20%-22% and tightening XIAFLEX guidance to high single-digits growth, along with pro forma net sales and Adjusted EBITDA guidance. This is a standard quarterly earnings release with material financial results and forward guidance.
View raw filing on EDGAR →This is a straightforward earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 11, 2026. The filing discloses quarterly financial results including R&D expenses ($11.7M), G&A expenses ($4.5M), net loss ($15.2M or $0.12 per share), and cash position ($208.3M), along with clinical development milestones and business highlights. The press release is furnished as Exhibit 99.1 and is the primary content of Item 2.02, which is the standard Item for earnings disclosures.
View raw filing on EDGAR →The filing discloses Vestis Corporation's financial results for the fiscal third quarter ended July 3, 2026, including revenue of $661.7 million, net income of $11.0 million, and Adjusted EBITDA of $80.9 million. The company also updated its full-year 2026 outlook, increasing Free Cash Flow guidance by $30 million. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →C4 Therapeutics issued a press release on August 11, 2026, announcing its financial results for the quarter ended June 30, 2026, including revenue ($6.6M), R&D expense ($24.5M), G&A expense ($8.6M), net loss ($23.6M), and cash position ($300.4M). The filing includes condensed consolidated balance sheet and statements of operations data, which are hallmarks of a quarterly earnings release under Item 2.02.
View raw filing on EDGAR →This is a press release announcing ECARX's unaudited financial results for the second quarter ended June 30, 2026. The document discloses Q2 2026 revenue of US$225.2 million (up 45% YoY), gross margin expansion from 10.8% to 19.8%, net loss reduction from US$45.4 million to US$12.0 million, and positive adjusted EBITDA of US$0.5 million. The company also reiterates full-year 2026 guidance of US$1.0–US$1.1 billion in total revenue. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →This is a press release announcing Organigram's third quarter fiscal 2026 financial results, disclosing record quarterly revenue of $145.1 million (gross) and $105.8 million (net), up 49% year-over-year, and adjusted EBITDA of $13.4 million, up 136% year-over-year. The release includes detailed financial statements, balance sheet metrics, and reconciliations of non-IFRS measures. While the exhibit also mentions the departure of CFO Paolo De Luca, the primary disclosure is the quarterly earnings announcement, which is material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →The filing discloses Bicara Therapeutics' financial results for Q2 2026 (ended June 30, 2026) via a press release furnished as Exhibit 99.1. The Item 2.02 disclosure includes key financial metrics: cash position of $497.3 million (up from $414.8 million at year-end 2025), R&D expenses of $45.8 million (up from $24.8 million YoY), G&A expenses of $14.2 million (up from $7.2 million YoY), and net loss of $55.4 million (up from $27.4 million YoY). While the filing also announces executive leadership transitions, the primary Item 2.02 disclosure centers on quarterly financial results and cash runway guidance through H1 2029, which is material to investor assessment of the company's financial condition and operational trajectory.
View raw filing on EDGAR →This exhibit is a 2Q26 Earnings Release from KT Corp presenting quarterly financial results including operating revenue (KRW 6,679.9bn), operating income (KRW 648.3bn), net income (KRW 480.6bn), and detailed segment performance across wireless, fixed-line, B2B services, and major subsidiaries. The document explicitly states "2Q26 Earnings Release" in the header and contains comprehensive financial highlights, income statements, balance sheets, and operational metrics typical of a quarterly results announcement.
View raw filing on EDGAR →Absci Corporation announced Q2 2026 financial results (revenue $0.3M, R&D expenses $22.6M, SG&A expenses $9.2M, net loss $33.2M, cash $201.1M) via press release on August 11, 2026, along with clinical trial updates including positive Phase 1 interim data from the HEADLINE trial of ABS-201 and a $100 million capital raise including a $40 million strategic investment from Eli Lilly.
View raw filing on EDGAR →This is a news release dated August 11, 2026, announcing BioHarvest's second quarter 2026 financial results. The exhibit discloses Q2 2026 revenues of $8.8 million (up 3.8% YoY), net loss of $3.7 million, and six-month results, along with revised full-year 2026 guidance. The document includes detailed financial statements (balance sheet, income statement, changes in equity) and is material to investors assessing the registrant's financial performance and trajectory.
View raw filing on EDGAR →Autolus Therapeutics disclosed Q2 2026 financial results on August 11, 2026, reporting net product revenue of $45.7 million (up 119% year-over-year), gross margin improvement to 55%, an operating loss of $43.8 million, and a net loss of $39.1 million. The company also provided updated full-year 2026 revenue guidance of $140–$150 million and discussed operational updates including a debt facility and workforce reduction.
View raw filing on EDGAR →